Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
PLoS One. 2013 May 14;8(5):e64416. doi: 10.1371/journal.pone.0064416. Print 2013.
Primarily arising from their well understood beneficial health effects, many lactobacilli strains are considered good candidates for use as probiotics in humans and animals. Lactobacillar probiosis can itself be best typified by the Lactobacillus rhamnosus GG strain, which, with its well-documented clinical benefits, has emerged as one of the most widely used probiotics in the food and health-supplement industries. Even so, many facets of its molecular mechanisms and limitations as a beneficial commensal bacterium still remain to be thoroughly explored and dissected. Because L. rhamnosus GG is one of only a few such strains exhibiting surface piliation (called SpaCBA), we sought to examine whether this particular type of cell-surface appendage has a discernible immunomodulating capacity and is able to trigger targeted responses in human immune-related cells. Thus, presented herein for this study, we recombinantly engineered Lactococcus lactis to produce native (and pilin-deleted) SpaCBA pili that were assembled in a structurally authentic form and anchored to the cell surface, and which had retained mucus-binding functionality. By using these recombinant lactococcal constructs, we were able to demonstrate that the SpaCBA pilus can be a contributory factor in the activation of Toll-like receptor 2-dependent signaling in HEK cells as well as in the modulation of pro- and anti-inflammatory cytokine (TNF-α, IL-6, IL-10, and IL-12) production in human monocyte-derived dendritic cells. From these data, we suggest that the recombinant-expressed and surface-anchored SpaCBA pilus, given its projected functioning in the gut environment, might be viewed as a new microbe-associated molecular pattern (MAMP)-like modulator of innate immunity. Accordingly, our study has brought some new insight to the molecular immunogenicity of the SpaCBA pilus, thus opening the way to a better understanding of its possible role in the multifaceted nature of L. rhamnosus GG probiosis within the human gut.
主要由于其被充分了解的有益健康的影响,许多乳杆菌菌株被认为是人类和动物中使用益生菌的良好候选者。乳杆菌益生菌本身可以以鼠李糖乳杆菌 GG 菌株为最佳代表,该菌株具有良好的临床益处,已成为食品和保健品行业中使用最广泛的益生菌之一。即便如此,作为有益共生菌的其分子机制和局限性的许多方面仍有待彻底探索和剖析。由于 L. rhamnosus GG 是少数具有表面菌毛(称为 SpaCBA)的菌株之一,我们试图研究这种特殊类型的细胞表面附属物是否具有可识别的免疫调节能力,并能够在人类免疫相关细胞中引发靶向反应。因此,在此研究中,我们重组工程化了 Lactococcus lactis 以产生天然(和无菌毛)SpaCBA 菌毛,这些菌毛以结构上真实的形式组装并锚定在细胞表面上,并保留了粘液结合功能。通过使用这些重组乳球菌构建体,我们能够证明 SpaCBA 菌毛可以作为 HEK 细胞中 Toll 样受体 2 依赖性信号转导的激活以及在人单核细胞衍生树突状细胞中促炎和抗炎细胞因子(TNF-α、IL-6、IL-10 和 IL-12)产生的调节中的一个贡献因素。从这些数据中,我们认为表达和表面锚定的 SpaCBA 菌毛,鉴于其在肠道环境中的预期作用,可能被视为先天免疫的新型微生物相关分子模式(MAMP)样调节剂。因此,我们的研究为 SpaCBA 菌毛的分子免疫原性提供了一些新的见解,从而为更好地理解其在 L. rhamnosus GG 益生菌在人类肠道中的多方面性质中的可能作用开辟了道路。